Literature DB >> 15200030

Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.

Satoru Kohgo1, Kohei Yamada, Kenji Kitano, Yuko Iwai, Shinji Sakata, Noriyuki Ashida, Hiroyuki Hayakawa, Daisuke Nameki, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya, Hiroshi Ohrui.   

Abstract

Some 4'-C-ethynyl-2'-deoxy purine nucleosides showed the most potent anti-HIV activity among the series of 4'-C-substituted 2'-deoxynucleosides whose 4'-C-substituents were methyl, ethyl, ethynyl and so on. Our hypothesis is that the smaller the substituent at the C-4' position they have, the more acceptable biological activity they show. Thus, 4'-C-cyano-2'-deoxy purine nucleosides, whose substituent is smaller than the ethynyl group, will have more potent antiviral activity. To prove our hypothesis, we planned to develop an efficient synthesis of 4'-C-cyano-2'-deoxy purine nucleosides (4'-CNdNs) and 4'-C-ethynyl-2'-deoxy purine nucleosides (4'-EdNs). Consequently, we succeeded in developing an efficient synthesis of six 2'-deoxy purine nucleosides bearing either a cyano or an ethynyl group at the C-4' position of the sugar moiety from 2'-deoxyadenosine and 2,6-diaminopurine 2'-deoxyriboside. Unfortunately, 4'-C-cyano derivatives showed lower activity against HIV-1, and two 4'-C-ethynyl derivatives suggested high toxicity in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200030     DOI: 10.1081/NCN-120037508

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  11 in total

1.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Pharmacokinetics studies of 4'-cyano-2'-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats.

Authors:  Mai Hashimoto; Kazuaki Taguchi; Takako Ishiguro; Satoru Kohgo; Shuhei Imoto; Keishi Yamasaki; Hiroaki Mitsuya; Masaki Otagiri
Journal:  J Pharm Pharmacol       Date:  2018-03-12       Impact factor: 3.765

3.  4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.

Authors:  Yuki Takamatsu; Yasuhito Tanaka; Satoru Kohgo; Shuko Murakami; Kamalendra Singh; Debananda Das; David J Venzon; Masayuki Amano; Nobuyo Higashi-Kuwata; Manabu Aoki; Nicole S Delino; Sanae Hayashi; Satoru Takahashi; Yoshikazu Sukenaga; Kazuhiro Haraguchi; Stefan G Sarafianos; Kenji Maeda; Hiroaki Mitsuya
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

4.  The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Authors:  Yuki Takamatsu; Debananda Das; Satoru Kohgo; Hironori Hayashi; Nicole S Delino; Stefan G Sarafianos; Hiroaki Mitsuya; Kenji Maeda
Journal:  Cell Chem Biol       Date:  2018-08-30       Impact factor: 8.116

5.  7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.

Authors:  Sanae Hayashi; Nobuyo Higashi-Kuwata; Debananda Das; Kota Tomaya; Kohei Yamada; Shuko Murakami; David J Venzon; Shin-Ichiro Hattori; Masanori Isogawa; Stefan G Sarafianos; Hiroaki Mitsuya; Yasuhito Tanaka
Journal:  Antiviral Res       Date:  2020-02-18       Impact factor: 5.970

6.  Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.

Authors:  Hiroshi Ohrui
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

7.  Pharmacokinetic properties of a novel inosine analog, 4'-cyano-2'-deoxyinosine, after oral administration in rats.

Authors:  Mai Hashimoto; Kazuaki Taguchi; Takako Ishiguro; Satoru Kohgo; Shuhei Imoto; Keishi Yamasaki; Hiroaki Mitsuya; Masaki Otagiri
Journal:  PLoS One       Date:  2018-06-06       Impact factor: 3.240

Review 8.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

9.  Acetylated and methylated β-cyclodextrins as viable soluble supports for the synthesis of short 2′-oligodeoxyribo-nucleotides in solution.

Authors:  Alejandro Gimenez Molina; Vyacheslav Kungurtsev; Pasi Virta; Harri Lönnberg
Journal:  Molecules       Date:  2012-10-16       Impact factor: 4.411

10.  Pharmacokinetic Properties of Orally Administered 4'-Cyano-2'-deoxyguanosine, a Novel Nucleoside Analog Inhibitor of the Hepatitis B Virus, in Viral Liver Injury Model Rats.

Authors:  Mai Hashimoto; Kazuaki Taguchi; Shuhei Imoto; Keishi Yamasaki; Hiroaki Mitsuya; Masaki Otagiri
Journal:  Biol Pharm Bull       Date:  2020       Impact factor: 2.233

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.